Collectively, our results identify a novel USP7–FBP1–DNMT1 signaling axis in pancreatic cancer, which might indicate that USP7 inhibitors and PARP inhibitors might have more powerful antitumor effects than PARP inhibitors alone in pancreatic cancer patients. Here, FBP1 is linked to familial pancreatic carcinoma.